Patents by Inventor Matthew B. Soellner
Matthew B. Soellner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399312Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: April 27, 2023Publication date: December 14, 2023Inventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
-
Patent number: 11673879Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: GrantFiled: March 30, 2021Date of Patent: June 13, 2023Assignee: Theravance Biopharma R&D IP, LLCInventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
-
Publication number: 20220372015Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: March 30, 2021Publication date: November 24, 2022Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Mandy Loo, Svitlana Kulyk, Christopher Bailey, Jennifer Kozak, Matthew B. Soellner, Adam D. Hughes
-
Patent number: 10196378Abstract: Inhibitor compounds of Bcr-Abl and Bcr-Abl mutants including Bcr-Abl T315I mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.Type: GrantFiled: August 24, 2017Date of Patent: February 5, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Matthew B. Soellner, Sameer Phadke
-
Publication number: 20180057479Abstract: Inhibitor compounds of Bcr-Abl and Bcr-Abl mutants including Bcr-Abl T315I mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.Type: ApplicationFiled: August 24, 2017Publication date: March 1, 2018Inventors: Matthew B. Soellner, Sameer Phadke
-
Patent number: 8962001Abstract: A class of anionic oligomers and polymers that function for inhibition of nucleases, particularly RNase. Specific inhibitors include mixtures of oligomers of vinyl sulfate. Methods for inhibition or inactivation of one or more nucleases in vitro which comprises the step of contacting the one or more nucleases in a biological medium with one or more of the anionic oligomeric or polymeric inhibitors of this invention. Kits for carrying out a biological procedure, biological reaction and/or a biological assay containing one or more inhibitors of this invention. The use of oligomers and/or polymers of this invention as additives in buffers or reagents. The inhibitors of the invention can also be attached to surfaces to provide for removal of nucleases from media, solutions or other liquids in contact with the solid.Type: GrantFiled: June 10, 2013Date of Patent: February 24, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Bryan D. Smith, Matthew B. Soellner, David M. Lynn
-
Publication number: 20130344563Abstract: A class of anionic oligomers and polymers that function for inhibition of nucleases, particularly RNase. Specific inhibitors include mixtures of oligomers of vinyl sulfate. Methods for inhibition or inactivation of one or more nucleases in vitro which comprises the step of contacting the one or more nucleases in a biological medium with one or more of the anionic oligomeric or polymeric inhibitors of this invention. Kits for carrying out a biological procedure, biological reaction and/or a biological assay containing one or more inhibitors of this invention. The use of oligomers and/or polymers of this invention as additives in buffers or reagents. The inhibitors of the invention can also be attached to surfaces to provide for removal of nucleases from media, solutions or other liquids in contact with the solid.Type: ApplicationFiled: June 10, 2013Publication date: December 26, 2013Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Ronald T. RAINES, Bryan D. Smith, Matthew B. Soellner, David M. Lynn
-
Patent number: 8460684Abstract: A class of anionic oligomers and polymers that function for inhibition of nucleases, particularly RNase. Specific inhibitors include mixtures of oligomers of vinyl sulfate. Methods for inhibition or inactivation of one or more nucleases in vitro which comprises the step of contacting the one or more nucleases in a biological medium with one or more of the anionic oligomeric or polymeric inhibitors of this invention. Kits for carrying out a biological procedure, biological reaction and/or a biological assay containing one or more inhibitors of this invention. The use of oligomers and/or polymers of this invention as additives in buffers or reagents. The inhibitors of the invention can also be attached to surfaces to provide for removal of nucleases from media, solutions or other liquids in contact with the solid.Type: GrantFiled: March 18, 2005Date of Patent: June 11, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Bryan D. Smith, Matthew B. Soellner, David M. Lynn
-
Patent number: 8410247Abstract: Water soluble reagents and methods for the formation of an amide bond between a phosphinothioester and an azide in an aqueous medium. The phosphinothioester is generated using a water-soluble phosphinothiol reagent. This reaction allows formation of an amide bond between a wide variety of chemical species including amino acids, peptides or protein fragments in an aqueous solution. Of particular interest, this reaction allows for the formation of an amide bond in a physiological setting. In a specific embodiment, this invention provides reagents and methods for peptide ligation in an aqueous medium. The reaction eliminates the need for a cysteine residue and is traceless leaving no residual atoms in the ligated peptide product.Type: GrantFiled: August 24, 2009Date of Patent: April 2, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Annie Tam, Matthew B. Soellner
-
Publication number: 20100048866Abstract: Water soluble reagents and methods for the formation of an amide bond between a phosphinothioester and an azide in an aqueous medium. The phosphinothioester is generated using a water-soluble phosphinothiol reagent. This reaction allows formation of an amide bond between a wide variety of chemical species including amino acids, peptides or protein fragments in an aqueous solution. Of particular interest, this reaction allows for the formation of an amide bond in a physiological setting. In a specific embodiment, this invention provides reagents and methods for peptide ligation in an aqueous medium. The reaction eliminates the need for a cysteine residue and is traceless leaving no residual atoms in the ligated peptide product.Type: ApplicationFiled: August 24, 2009Publication date: February 25, 2010Inventors: Ronald T. Raines, Annie Tam, Matthew B. Soellner
-
Patent number: 7317129Abstract: The present invention provides improved methods for synthesis of phosphinothiol reagents, as well as novel protected reagents, for use in formation of amide bonds, and particularly, for peptide ligation. The invention provides phosphine-borane complexes useful as reagents in the formation of amide bonds, particularly for the formation of an amide bond between any two of an amino acid, a peptide, or a protein.Type: GrantFiled: September 19, 2005Date of Patent: January 8, 2008Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Laura L. Kiessling, Bradley L. Nilsson, Yi He, Matthew B. Soellner, Ronald J. Hinklin
-
Patent number: 7256259Abstract: The present invention is a method for a covalent ligation of one or more molecules to one or more surfaces, that is site-specific and both rapid and high yielding. The covalent ligation to the surface is based on the reaction of an azide and a phosphinothioester to form an amide bond. The method of the invention is particularly well-suited to the immobilization of peptides, proteins or protein fragments to surfaces.Type: GrantFiled: August 30, 2004Date of Patent: August 14, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Matthew B. Soellner
-
Patent number: 6974884Abstract: The present invention provides improved methods for synthesis of phosphinothiol reagents, as well as novel protected reagents, for use in formation of amide bonds, and particularly for peptide ligation. The invention provides phosphine-borane complexes useful as reagents in the formation of amide bonds, particularly for the formation of an amide bond between any two of an amino acid, a peptide, or a protein.Type: GrantFiled: June 6, 2003Date of Patent: December 13, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Laura L. Kiessling, Bradley L. Nilsson, Yi He, Matthew B. Soellner, Ronald J. Hinklin
-
Publication number: 20040030105Abstract: The present invention provides improved methods for synthesis of phosphinothiol reagents, as well as novel protected reagents, for use in formation of amide bonds, and particularly for peptide ligation. The invention provides phosphine-borane complexes useful as reagents in the formation of amide bonds, particularly for the formation of an amide bond between any two of an amino acid, a peptide, or a protein.Type: ApplicationFiled: June 6, 2003Publication date: February 12, 2004Inventors: Ronald T. Raines, Laura L. Kiessling, Bradley L. Nilsson, Yi He, Matthew B. Soellner, Ronald J. Hinklin